Bendroflumethiazide
Based on 1 Customer Validation
Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus.
For research use only. We do not sell to patients.
- Purity: 99.16%
- CAS No.: 73-48-3
- Formula: C15H14F3N3O4S2
- Molecular Weight:421.41
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Brattleboro rats with hereditary DI (female 200 g) [2]
-
Dosage:125 mg/kg
-
Administration:p.o., 12 days
-
Result:Showed a weight loss of approximately 3%, but did not change average daily food intake.
Reduced urine flow, increased urine osmotic pressure, and reduced free water clearance.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 73-48-3
-
Appearance Solid
-
Molecular Weight 421.41
-
Formula C15H14F3N3O4S2
-
Color Off-white to light yellow
-
SMILES
O=S(C1=C(C(F)(F)F)C=C(C2=C1)NC(CC3=CC=CC=C3)NS2(=O)=O)(N)=O
-
Synonyms
Bendrofluazide
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 250 mg/mL (593.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tamargo J, et al. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014 Mar;15(4):527-47. [Content Brief]
[2]. Grønbeck L, et al. Mechanism of antidiuresis caused by bendroflumethiazide in conscious rats with diabetes insipidus. Br J Pharmacol. 1998 Feb;123(4):737-45. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3730 mL | 11.8649 mL | 23.7299 mL | 59.3246 mL |
| 5 mM | 0.4746 mL | 2.3730 mL | 4.7460 mL | 11.8649 mL | |
| 10 mM | 0.2373 mL | 1.1865 mL | 2.3730 mL | 5.9325 mL | |
| 15 mM | 0.1582 mL | 0.7910 mL | 1.5820 mL | 3.9550 mL | |
| 20 mM | 0.1186 mL | 0.5932 mL | 1.1865 mL | 2.9662 mL | |
| 25 mM | 0.0949 mL | 0.4746 mL | 0.9492 mL | 2.3730 mL | |
| 30 mM | 0.0791 mL | 0.3955 mL | 0.7910 mL | 1.9775 mL | |
| 40 mM | 0.0593 mL | 0.2966 mL | 0.5932 mL | 1.4831 mL | |
| 50 mM | 0.0475 mL | 0.2373 mL | 0.4746 mL | 1.1865 mL | |
| 60 mM | 0.0395 mL | 0.1977 mL | 0.3955 mL | 0.9887 mL | |
| 80 mM | 0.0297 mL | 0.1483 mL | 0.2966 mL | 0.7416 mL | |
| 100 mM | 0.0237 mL | 0.1186 mL | 0.2373 mL | 0.5932 mL |
Bendroflumethiazide Related Classifications
HY-B1363 Related Classifications
Powered by Bioz